History of B2B

From discovery to long-term understanding

The Bench to Bassinet (B2B) Program was launched by the National Heart, Lung, and Blood Institute (NHLBI) in 2009 as a novel approach to break through the major barriers of translational research, identify the causes of human congenital heart disease (CHD), and ultimately improve outcomes for individuals with CHD.

The initial focus of B2B was data generation describing the developmental biology and genetic basis of CHD. The program included two consortia designed to inform each other’s work: the Pediatric Cardiac Genomics Consortium (PCGC) and the Cardiac Developmental Data Research Center (CDDRC).

Two connected research programs

Pediatric Cardiac Genomics Consortium

The PCGC was a group of clinical research teams that collaborated to identify genetic causes of human congenital heart disease and to relate genetic variants present in the congenital heart disease patient population to clinical outcomes.

The B2B story

The program grew from a shared research initiative into a substantial resource of genetic, clinical, imaging, and neurodevelopmental data.

Launching Bench to Bassinet

In 2009, the Bench to Bassinet Program was launched by NHLBI with the Pediatric Cardiac Genomics Consortium and the Cardiac Developmental Data Research Center designed to inform each other’s work.

Building the CHD GENES research resource

Beginning in 2010, the Congenital Heart Disease GEnetic NEtwork Study (CHD GENES) was a multi-center prospective observational cohort study that investigated the relationship between genetic factors and phenotypic and clinical outcomes in patients with congenital heart defects.

Through the CHD GENES study, the PCGC enrolled and conducted genomic sequencing on over 14,000 participants with CHD and 18,000 family members from 2010 to 2025. CHD GENES data is a valuable resource of human genetic and clinical data shared through the NHLBI BioData Catalyst platform.

Expanding coordination and research

In 2016, Cincinnati Children’s Hospital and Medical Center (CCHMC) assumed responsibility as the Administrative and Data Coordinating Center.

B2B partnered with the National Institute of Child Health and Human Development (NICHD) to develop the CHD Brain and Genes sub-study, which was implemented by Jane Newburger, MD (Boston Children’s Hospital) and Eileen King, PhD (CCHMC) to study brain MRI and complete neurodevelopmental assessments on a subset of CHD GENES participants.